Cellosaurus IGROV-1/Pt1 (CVCL_EQ62)

Cell line name IGROV-1/Pt1
Synonyms IGROV-1/Pt 1; IGROV1/Pt1
Accession CVCL_EQ62
Resource Identification Initiative To cite this cell line use: IGROV-1/Pt1 (RRID:CVCL_EQ62)
Comments Doubling time: 33 +- 2 hours (PubMed=9636834).
Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
Sequence variations Heterozygous for BRCA1 p.Lys654fs*47 (c.1961delA) (from parent cell line).
Heterozygous for SMAD4 p.Gly231fs*10 (c.692delG) (from parent cell line).
Heterozygous for PTEN p.Thr319fs*1 (c.955_958delACTT) (from parent cell line).
Heterozygous for TP53 p.Tyr126Cys (c.377A>G) (from parent cell line).
Heterozygous for TP53 p.Phe270Leu (c.808T>C) and p.Arg282Trp (c.844C>T) (PubMed=8564971).
Disease Ovarian endometrioid adenocarcinoma (NCIt: C7979)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_1304 (IGROV-1)
Sex of cell Female
Age at sampling 47Y
Category Cancer cell line
Publications

PubMed=8564971
Perego P., Giarola M., Righetti S.C., Supino R., Caserini C., Delia D., Pierotti M.A., Miyashita T., Reed J.C., Zunino F.
Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Cancer Res. 56:556-562(1996)

PubMed=9636834; DOI=10.1023/A:1008265012435
Perego P., Romanelli S., Carenini N., Magnani I., Leone R., Bonetti A., Paolicchi A., Zunino F.
Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to taxol.
Ann. Oncol. 9:423-430(1998)

Cross-references
Other Wikidata; Q54897388